Resource Library
Mitigating early development risks with Samsung Biologics DEVELOPICK™ platform
Early identification of promising drug candidates is critical for safe and efficient development. In our latest whitepaper, Heonchang Lim, Director of Formulation Development, explains how we leverage our proprietary DEVELOPICK™ platform to streamline the discovery process, enhancing the likelihood of successful drug commercialization. Read more
The critical role of drug developability assessments
Accurately predicting candidate performance during the discovery phase is a pivotal strategy for reducing the time and expense involved in drug development. Effective early-stage candidate selection conserves resources to focus on molecules with promising developability profiles. This increases the likelihood of preventing expensive late-stage failures and achieving safety, efficacy, and manufacturability standards for successful commercialization.
Critical considerations in assessing the developability of a biotherapeutic include:
- Potency
- Specificity
- Immunogenicity
- Pharmacokinetics
- Biophysical properties during in vivo activities
- Storage
Target identification and selection using the DEVELOPICK™ platform
Using the DEVELOPICK™ platform to comprehensively assess developability provides early and critical insights into the attributes of candidates, including safety, efficacy, and manufacturability. The systematic evaluation of multiple candidates through the platform identifies the most promising molecules to advance into preclinical testing. In addition, the unique array of analytical tools DEVELOPICK™ employs delivers extensive and valuable data quickly and efficiently, using only minimal material (80 milligrams). Most notably, these thorough assessments yield results within just one month.
Early identification of promising drug candidates is critical for safe and efficient development. In our latest whitepaper, Heonchang Lim, Director of Formulation Development, explains how we leverage our proprietary DEVELOPICK™ platform to streamline the discovery process, enhancing the likelihood of successful drug commercialization. Read more
The critical role of drug developability assessments
Accurately predicting candidate performance during the discovery phase is a pivotal strategy for reducing the time and expense involved in drug development. Effective early-stage candidate selection conserves resources to focus on molecules with promising developability profiles. This increases the likelihood of preventing expensive late-stage failures and achieving safety, efficacy, and manufacturability standards for successful commercialization.
Critical considerations in assessing the developability of a biotherapeutic include:
- Potency
- Specificity
- Immunogenicity
- Pharmacokinetics
- Biophysical properties during in vivo activities
- Storage
Target identification and selection using the DEVELOPICK™ platform
Using the DEVELOPICK™ platform to comprehensively assess developability provides early and critical insights into the attributes of candidates, including safety, efficacy, and manufacturability. The systematic evaluation of multiple candidates through the platform identifies the most promising molecules to advance into preclinical testing. In addition, the unique array of analytical tools DEVELOPICK™ employs delivers extensive and valuable data quickly and efficiently, using only minimal material (80 milligrams). Most notably, these thorough assessments yield results within just one month.